OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis → 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad) Free ARTH Stock Alerts $1.18 +0.02 (+1.72%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$1.16▼$1.2050-Day Range$1.12▼$3.0952-Week Range$0.39▼$18.00Volume6,887 shsAverage Volume3,038 shsMarket Capitalization$5.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Arch Therapeutics alerts: Email Address Ad DarwinYour Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your report About Arch Therapeutics Stock (OTCMKTS:ARTH)Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Read More ARTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTH Stock News HeadlinesApril 12, 2024 | americanbankingnews.comArch Therapeutics (OTCMKTS:ARTH) Shares Pass Below 50-Day Moving Average of $2.23February 8, 2024 | msn.comArch Therapeutics Secures $750K Prepayment for StockApril 19, 2024 | DTI (Ad)Start loving Mondays like thisWouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!January 6, 2024 | morningstar.comArch Therapeutics Inc ARTHNovember 23, 2023 | msn.comAre Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?November 9, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Provides Year End Operational UpdateNovember 9, 2023 | finance.yahoo.comArch Therapeutics Provides Year End Operational UpdateNovember 2, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)April 19, 2024 | DTI (Ad)Start loving Mondays like thisWouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!September 13, 2023 | finance.yahoo.comArch Therapeutics Provides AC5® Commercialization UpdateSeptember 8, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to UplistingSeptember 7, 2023 | finance.yahoo.comArch Therapeutics Completes Financing as Bridge to UplistingJuly 8, 2023 | health.usnews.comDr. Arth PatelJune 13, 2023 | travel.usnews.comDouble ArchApril 25, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)April 5, 2023 | finance.yahoo.comDedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In EffectMarch 20, 2023 | investing.comArch Therapeutics Inc (ARTHD)March 9, 2023 | finance.yahoo.comArch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid ServicesMarch 7, 2023 | finance.yahoo.comArch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government FacilitiesFebruary 23, 2023 | benzinga.comArch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and RevenueJanuary 24, 2023 | msn.comWound products developer Arch Therapeutics files for uplisting, $35M offering (update)January 18, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeJanuary 18, 2023 | finance.yahoo.comArch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound SystemJanuary 17, 2023 | finance.yahoo.comArch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeDecember 5, 2022 | finance.yahoo.comThe Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound SystemOctober 20, 2022 | seekingalpha.comARTH Arch Therapeutics, Inc.October 18, 2022 | yahoo.comKey Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) FallSee More Headlines Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/19/2024Next Earnings (Estimated)5/20/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,980,000.00 Net Margins-6,809.45% Pretax Margin-6,808.58% Return on EquityN/A Return on Assets-386.74% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.04 Sales & Book Value Annual Sales$80,000.00 Price / Sales69.92 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / Book-0.49Miscellaneous Outstanding Shares4,740,000Free Float4,529,000Market Cap$5.59 million OptionableNot Optionable Beta3.52 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Terrence W. Norchi M.D. (Age 59)Co-Founder, Chairman, President & CEO Comp: $450.5kMr. Michael S. Abrams (Age 54)CFO & Treasurer Comp: $325kDr. Rutledge Ellis-Behnke Ph.D.Co-Founder & Scientific AdvisorMr. Shawn CarlsonVice President of SalesKey CompetitorsG Medical InnovationsNASDAQ:GMVDFTitan MedicalNASDAQ:TMDIFVenus ConceptNASDAQ:VEROSharps TechnologyNASDAQ:STSSMinerva SurgicalNASDAQ:UTRSView All Competitors ARTH Stock Analysis - Frequently Asked Questions How have ARTH shares performed in 2024? Arch Therapeutics' stock was trading at $7.24 on January 1st, 2024. Since then, ARTH shares have decreased by 83.7% and is now trading at $1.18. View the best growth stocks for 2024 here. When is Arch Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ARTH earnings forecast. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its quarterly earnings data on Tuesday, February, 20th. The biotechnology company reported ($0.57) EPS for the quarter. The biotechnology company earned $0.05 million during the quarter. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH). How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ARTH) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlace1970’s computer coder issues shocking A.I. warningTradeSmithSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.